Literature DB >> 17394874

[Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic].

Joaquim Gascón1, Pedro Albajar, Elías Cañas, María Flores, Jordi Gómez i Prat, Ramón N Herrera, Carlos A Lafuente, Héctor L Luciardi, Alvaro Moncayo, Lluís Molina, José Muñoz, Sabino Puente, Ginés Sanz, Begoña Treviño, Xavier Sergio-Salles.   

Abstract

Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17394874

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  26 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.

Authors:  Bruno Lisboa Timm; Patrícia Bernadino da Silva; Marcos Meuser Batista; Francisca Hildemagna Guedes da Silva; Cristiane França da Silva; Richard R Tidwell; Donald A Patrick; Susan Kilgore Jones; Stanislav A Bakunov; Svetlana M Bakunova; Maria de Nazaré C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Physician Knowledge of Chagas Disease in Hispanic Immigrants Living in Appalachian Ohio.

Authors:  Shelley Amstutz-Szalay
Journal:  J Racial Ethn Health Disparities       Date:  2016-06-20

4.  Lack of association between blood-based detection of Trypanosoma cruzi DNA and cardiac involvement in a non-endemic area.

Authors:  F F Norman; A Pérez-Ayala; J A Pérez-Molina; M Flores-Chavez; C Cañavate; R López-Vélez
Journal:  Ann Trop Med Parasitol       Date:  2011-09

Review 5.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  The investigation of congenital infection by Trypanosoma cruzi in an endemic area of Chile: three protocols explored in a pilot project.

Authors:  I Zulantay; G Corral; M C Guzman; F Aldunate; W Guerra; I Cruz; A Araya; V Tapia; F Marquez; C Muñoz; W Apt
Journal:  Ann Trop Med Parasitol       Date:  2011-03

7.  Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.

Authors:  José M Ramos; Diego Torrús; Concepción Amador; Francisco Jover; Fabiola Pérez-Chacón; Yamileth Ponce; Francisco J Arjona; Elena Caro; Concepción Martínez-Peinado; Ingrid Gallegos; José M Cuadrado; Antonio Tello; Felix Gutiérrez
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

8.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 9.  A systematic review of high quality diagnostic tests for Chagas disease.

Authors:  Anna M Afonso; Mark H Ebell; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2012-11-08

10.  Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor.

Authors:  Juan P Rigalli; Virginia G Perdomo; Marcelo G Luquita; Silvina S M Villanueva; Agostina Arias; Dirk Theile; Johanna Weiss; Aldo D Mottino; María L Ruiz; Viviana A Catania
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.